Pharmacogenomics in Tailoring First-Line Therapy for Breast Cancer: PharmGKB Database Insights

Abstract

ABSTRACTThis study delves into the role of pharmacogenomics in optimizing first-line breast cancer treatments, leveraging insights from the PharmGKB database. It emphasizes the importance of understanding genetic variations and their influence on the efficacy and side effects of key drugs like Letrozole, Anastrozole, Tamoxifen, Trastuzumab, and Pertuzumab. By analyzing these drugs in the context of genetic profiles, the research highlights the necessity of incorporating genetic testing into treatment planning. The findings underscore the potential of pharmacogenetics to personalize therapy, aiming to improve outcomes and reduce adverse reactions in breast cancer patients. This approach marks a significant stride towards tailored cancer treatments, underscoring the need for continued research in this field.